IPO registrations (S-1, F-1) · Registrants
Akari Therapeutics Plc
- SEC CIK
- 1541157 · filings on EDGAR ↗
- Former names
- Celsus Therapeutics Plc. (2012–2015); Morria Biopharmaceuticals PLC (2012–2013)
- Registration
- Form F-1, S-1, first filed 2012-12-03, last 2026-06-26; 14 initial registrations, 10 amendments
- Outcome
- Final prospectus filed 2014-01-31; declared effective 2012-12-07; withdrawal requested 2015-03-11
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- X0
- Business address
- 401 EAST JACKSON STREET, SUITE 3300, Tampa, FL 33602
- EIN
- 98-1034922
- Ticker
- AKTX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Akari Therapeutics Plc on the corporate pages
On this site
- Form D issuer: Akari Therapeutics Plc EXACT (CIK (EXACT))
- SEC filer: Akari Therapeutics Plc EXACT (CIK (EXACT))
Filings 77
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2012-12-03 | F-1 | F-1 (foreign registration) | Morria Biopharmaceuticals PLC | 0001144204-12-066135 ↗ |
| 2012-12-07 | EFFECT | EFFECT (declared effective) | Morria Biopharmaceuticals PLC | 9999999995-12-003476 ↗ |
| 2012-12-27 | F-1/A | F-1/A (amendment) | Morria Biopharmaceuticals PLC | 0001144204-12-069870 ↗ |
| 2013-01-22 | F-1/A | F-1/A (amendment) | Morria Biopharmaceuticals PLC | 0001144204-13-003478 ↗ |
| 2013-02-01 | EFFECT | EFFECT (declared effective) | Morria Biopharmaceuticals PLC | 9999999995-13-000360 ↗ |
| 2013-04-01 | EFFECT | EFFECT (declared effective) | Morria Biopharmaceuticals PLC | 9999999995-13-000850 ↗ |
| 2013-04-10 | F-1 | F-1 (foreign registration) | Morria Biopharmaceuticals PLC | 0001144204-13-020910 ↗ |
| 2013-04-16 | EFFECT | EFFECT (declared effective) | Morria Biopharmaceuticals PLC | 9999999995-13-001026 ↗ |
| 2013-10-24 | F-1 | F-1 (foreign registration) | Celsus Therapeutics Plc. | 0001144204-13-056677 ↗ |
| 2013-11-06 | EFFECT | EFFECT (declared effective) | Celsus Therapeutics Plc. | 9999999995-13-003204 ↗ |
| 2013-12-12 | F-1 | F-1 (foreign registration) | Celsus Therapeutics Plc. | 0001144204-13-066785 ↗ |
| 2014-01-07 | F-1/A | F-1/A (amendment) | Celsus Therapeutics Plc. | 0001144204-14-000833 ↗ |
| 2014-01-28 | F-1/A | F-1/A (amendment) | Celsus Therapeutics Plc. | 0001144204-14-004474 ↗ |
| 2014-01-30 | EFFECT | EFFECT (declared effective) | Celsus Therapeutics Plc. | 9999999995-14-000265 ↗ |
| 2014-01-31 | 424B4 | 424B4 (final prospectus) | Celsus Therapeutics Plc. | 0001144204-14-005134 ↗ |
| 2014-03-31 | EFFECT | EFFECT (declared effective) | Celsus Therapeutics Plc. | 9999999995-14-000824 ↗ |
| 2014-03-31 | EFFECT | EFFECT (declared effective) | Celsus Therapeutics Plc. | 9999999995-14-000828 ↗ |
| 2014-03-31 | EFFECT | EFFECT (declared effective) | Celsus Therapeutics Plc. | 9999999995-14-000830 ↗ |
| 2014-08-20 | EFFECT | EFFECT (declared effective) | Celsus Therapeutics Plc. | 9999999995-14-002571 ↗ |
| 2014-11-20 | S-1 | S-1 (registration) | Celsus Therapeutics Plc. | 0001144204-14-070095 ↗ |
| 2015-03-11 | RW | RW (withdrawal request) | Celsus Therapeutics Plc. | 0001144204-15-015277 ↗ |
| 2015-10-30 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-15-002919 ↗ |
| 2018-02-23 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-18-000489 ↗ |
| 2018-10-09 | F-1 | F-1 (foreign registration) | Akari Therapeutics Plc | 0001144204-18-052994 ↗ |
| 2019-02-14 | F-1/A | F-1/A (amendment) | Akari Therapeutics Plc | 0001144204-19-007765 ↗ |
| 2019-03-01 | F-1/A | F-1/A (amendment) | Akari Therapeutics Plc | 0001144204-19-011563 ↗ |
| 2019-03-04 | F-1/A | F-1/A (amendment) | Akari Therapeutics Plc | 0001144204-19-011699 ↗ |
| 2019-03-04 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-19-000360 ↗ |
| 2019-04-29 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-19-000885 ↗ |
| 2019-08-06 | F-1 | F-1 (foreign registration) | Akari Therapeutics Plc | 0001144204-19-037896 ↗ |
| 2019-08-30 | F-1/A | F-1/A (amendment) | Akari Therapeutics Plc | 0001144204-19-043013 ↗ |
| 2019-09-05 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-19-002018 ↗ |
| 2019-09-06 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-19-002036 ↗ |
| 2019-10-15 | F-1 | F-1 (foreign registration) | Akari Therapeutics Plc | 0001104659-19-054215 ↗ |
| 2019-10-25 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-19-002399 ↗ |
| 2020-04-16 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-20-000774 ↗ |
| 2020-04-17 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-20-000780 ↗ |
| 2020-05-11 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-20-001111 ↗ |
| 2020-07-17 | F-1 | F-1 (foreign registration) | Akari Therapeutics Plc | 0001104659-20-084530 ↗ |
| 2020-07-27 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-20-001932 ↗ |
| 2020-09-18 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-20-002497 ↗ |
| 2020-09-18 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-20-002498 ↗ |
| 2020-09-18 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-20-002499 ↗ |
| 2020-09-18 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-20-002500 ↗ |
| 2020-12-31 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-21-000013 ↗ |
| 2021-04-30 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-21-001639 ↗ |
| 2021-04-30 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-21-001645 ↗ |
| 2021-04-30 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-21-001646 ↗ |
| 2021-04-30 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-21-001663 ↗ |
| 2021-08-31 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-21-003368 ↗ |
| 2021-10-01 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-21-003732 ↗ |
| 2021-10-01 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-21-003733 ↗ |
| 2021-10-01 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-21-003734 ↗ |
| 2021-10-01 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-21-003736 ↗ |
| 2022-10-12 | F-1 | F-1 (foreign registration) | Akari Therapeutics Plc | 0001104659-22-108100 ↗ |
| 2022-11-04 | F-1/A | F-1/A (amendment) | Akari Therapeutics Plc | 0001104659-22-114953 ↗ |
| 2022-11-08 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-22-003234 ↗ |
| 2023-06-06 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-23-001636 ↗ |
| 2023-06-06 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-23-001639 ↗ |
| 2023-10-23 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-23-003060 ↗ |
| 2023-10-23 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-23-003062 ↗ |
| 2023-10-26 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-23-003103 ↗ |
| 2024-09-13 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-24-002847 ↗ |
| 2024-10-11 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-24-003169 ↗ |
| 2025-05-14 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-25-001605 ↗ |
| 2025-07-31 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-25-002439 ↗ |
| 2025-08-29 | S-1 | S-1 (registration) | Akari Therapeutics Plc | 0001641172-25-026052 ↗ |
| 2025-11-17 | S-1 | S-1 (registration) | Akari Therapeutics Plc | 0001493152-25-023908 ↗ |
| 2025-12-02 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-25-003483 ↗ |
| 2026-01-23 | S-1 | S-1 (registration) | Akari Therapeutics Plc | 0001493152-26-003458 ↗ |
| 2026-01-29 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-26-000356 ↗ |
| 2026-04-15 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-26-001192 ↗ |
| 2026-05-08 | S-1 | S-1 (registration) | Akari Therapeutics Plc | 0001493152-26-022019 ↗ |
| 2026-05-21 | RW | RW (withdrawal request) | Akari Therapeutics Plc | 0001493152-26-024741 ↗ |
| 2026-06-26 | S-1/A | S-1/A (amendment) | Akari Therapeutics Plc | 0001493152-26-030330 ↗ |
| 2026-07-07 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-26-002205 ↗ |
| 2026-07-13 | EFFECT | EFFECT (declared effective) | Akari Therapeutics Plc | 9999999995-26-002279 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Mintz Hal | TenPercentOwner | 8 | 2014 | ||
| Sabby Healthcare Volatility Master Fund, Ltd. | TenPercentOwner | 8 | 2014 | ||
| SABBY MANAGEMENT, LLC | TenPercentOwner | 8 | 2014 | ||
| Cohen Mark S | Director | 5 | 2015–2016 | ||
| Doman Robert F | Director | 1 | 2015 | ||
| EIRAN AMOS | Director | 1 | 2015 | ||
| Elefant Dov | Officer | Chief Financial Officer | 2 | 2015 | |
| Jimenez Pablo | Officer | Chief Medical Officer | 1 | 2015 | |
| LAU JOHNSON YIU NAM | Director | 1 | 2015 | ||
| Roshwalb Gur | Director,Officer | Chief Executive Officer | 2 | 2015 | |
| Shaw Allan | Director | 3 | 2015 | ||
| SIDRANSKY DAVID | Director | 1 | 2015 | ||
| Hill James | Director; Director,TenPercentOwner | 4 | 2015–2016 | ||
| Prudo-Chlebosz Raymond | Director; Director,TenPercentOwner | 8 | 2015–2025 | ||
| Richardson Clive | Director,Officer | COO | 2 | 2015 | |
| RPC Pharma Ltd | TenPercentOwner | 1 | 2015 | ||
| Ungar Stuart | Director; Director,TenPercentOwner | 4 | 2015–2016 | ||
| SHAW ROBERT M | Officer | General Counsel and Secretary | 2 | 2016 | |
| Byrne David | Director | 3 | 2016 | ||
| Williams Donald Allen | Director | 2 | 2016 | ||
| DICICCO WENDY F | Officer | Interim CFO | 2 | 2024 | |
| Grissinger Michael | Director | 2 | 2024 | ||
| Hashad Mohamed Wa'el Ahmed | Director | 2 | 2024 | ||
| Jacques Rachelle Suzanne | Director,Officer | Chief Executive Officer | 2 | 2024 | |
| Patel Samir Rashmikant | Director; Director,TenPercentOwner | 16 | 2024–2026 | ||
| WILLIAMS DONALD A | Director | 2 | 2024 | ||
| Bazemore Robert B | Director | 5 | 2024–2025 | ||
| Huh Hoyoung | Director,TenPercentOwner | 4 | 2024–2025 | ||
| Neal James R | Director | 6 | 2024–2026 | ||
| Patel Sandip I | Director | 4 | 2024–2025 | ||
| Hombeck Torsten | Officer | CFO | 3 | 2024–2025 | |
| Gaslightwala Abizer | Director; Director,Officer | CEO; President & CEO | 16 | 2024–2026 | |
| Farag Kameel D. | Officer | Interim CFO | 7 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-06-03 | Akari Therapeutics Plc | Other Health Care | $5,500,000 | $1,833,333 | 6 | 1 |
| 2025-10-24 | Akari Therapeutics Plc | Other Health Care | $6,250,000 | $6,250,000 | 4 | 1 |
| 2024-01-09 | Akari Therapeutics Plc | Other Health Care | $2,000,001 | $2,000,001 | 2 | 1 |
| 2023-10-19 | Akari Therapeutics Plc | Other Health Care | $1,971,001 | $1,971,001 | 11 | 1 |
| 2022-09-27 | Akari Therapeutics Plc | Biotechnology | $12,835,000 | $12,835,000 | 21 | 1 |
| 2021-07-22 | Akari Therapeutics Plc | Biotechnology | $12,318,688 | $12,318,688 | 62 | 1 |
| 2020-03-11 | Akari Therapeutics Plc | Biotechnology | $9,554,528 | $9,554,528 | 53 | 1 |
| 2019-07-12 | Akari Therapeutics Plc | Biotechnology | $4,499,945 | $4,499,945 | 45 | 1 |
| 2015-09-28 | Akari Therapeutics Plc | Biotechnology | $75,000,000 | $75,000,000 | 28 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.